[go: up one dir, main page]

PE20151783A1 - Dispersion solida de un modulador selectivo de los receptores de progesterona - Google Patents

Dispersion solida de un modulador selectivo de los receptores de progesterona

Info

Publication number
PE20151783A1
PE20151783A1 PE2015000745A PE2015000745A PE20151783A1 PE 20151783 A1 PE20151783 A1 PE 20151783A1 PE 2015000745 A PE2015000745 A PE 2015000745A PE 2015000745 A PE2015000745 A PE 2015000745A PE 20151783 A1 PE20151783 A1 PE 20151783A1
Authority
PE
Peru
Prior art keywords
solid dispersion
progesterone receptors
norpregna
11beta
acetoxy
Prior art date
Application number
PE2015000745A
Other languages
English (en)
Inventor
Florian Battung
Pierre-Yves Juvin
Jerôme Hecq
Aude Colin
Original Assignee
Hra Pharma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47878221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151783(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hra Pharma Lab filed Critical Hra Pharma Lab
Publication of PE20151783A1 publication Critical patent/PE20151783A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Colloid Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referida a una dispersion solida que comprende un principio activo seleccionado entre el grupo que consiste en moduladores selectivos de los receptores de progesterona, metabolitos de los mismos y mezclas de los mismos, y un excipiente polimerico farmaceuticamente aceptable. El principio activo es 17 alfa-acetoxi-11beta-[4-n-metilaminofenil]-19-norpregna-4,9-dieno-3, 20-diona, 17alfa-acetoxi-11beta-[4-aminofenil]-19-norpregna-4,9-dieno-3,20-diona, acetato de ulipristal y mezclas de los mismos. La invencion tambien se refiere a una composicion farmaceutica util para el tratamiento o prevencion de un trastorno ginecologico, asi como tambien para uso anticonceptivo
PE2015000745A 2012-12-06 2013-12-05 Dispersion solida de un modulador selectivo de los receptores de progesterona PE20151783A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1261721A FR2999081B1 (fr) 2012-12-06 2012-12-06 Dispersion solide d'un modulateur selectif du recepteur a la progesterone

Publications (1)

Publication Number Publication Date
PE20151783A1 true PE20151783A1 (es) 2015-12-20

Family

ID=47878221

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000745A PE20151783A1 (es) 2012-12-06 2013-12-05 Dispersion solida de un modulador selectivo de los receptores de progesterona

Country Status (19)

Country Link
US (1) US20160213684A1 (es)
EP (1) EP2928499B1 (es)
JP (1) JP2016506390A (es)
CN (1) CN105120899B (es)
BR (1) BR112015013110B1 (es)
CL (1) CL2015001559A1 (es)
CR (1) CR20150299A (es)
DO (1) DOP2015000137A (es)
EA (1) EA029701B1 (es)
EC (1) ECSP15022501A (es)
ES (1) ES2666618T3 (es)
FR (1) FR2999081B1 (es)
GE (1) GEP201706740B (es)
MD (1) MD4591C1 (es)
MX (1) MX362151B (es)
NI (1) NI201500076A (es)
PE (1) PE20151783A1 (es)
UA (1) UA115796C2 (es)
WO (1) WO2014087106A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12133911B2 (en) 2015-06-09 2024-11-05 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
FR3060389B1 (fr) 2016-12-20 2019-05-31 Laboratoire Hra-Pharma Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
EP3492070A1 (en) * 2017-11-30 2019-06-05 BIT Pharma GmbH Process and device for preparing a solid dispersion
CN108186586B (zh) * 2018-03-01 2020-12-29 常州市第四制药厂有限公司 一种烯丙雌醇片剂及其制备方法
EP3895691A1 (en) * 2020-04-15 2021-10-20 LTS Lohmann Therapie-Systeme AG Ulipristal acetate otf
CN111714444B (zh) * 2020-06-23 2022-12-20 南京海纳医药科技股份有限公司 一种醋酸乌利司他口服固体制剂及其制备方法
CN113406230A (zh) * 2021-06-17 2021-09-17 河南泰丰生物科技有限公司 一种醋酸乌利司他固体制剂溶出曲线的测定方法
WO2023033900A1 (en) 2021-09-06 2023-03-09 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FI962978A7 (fi) * 1994-07-26 1997-01-20 Laboratoires Effik Kuivien lääkevalmisteiden valmistusmenetelmä ja näin saadut lääkeaines eokset
AU730216B2 (en) * 1996-09-01 2001-03-01 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
AU2005265357B2 (en) 2004-07-09 2011-04-07 Laboratoire Hra Pharma Sustained release compositions containing progesterone receptor modulators
MX2009006912A (es) * 2006-12-28 2009-08-12 Repros Therapeutics Inc Metodos y formulaciones para biodisponibilidad mejorada de antiprogestinas.
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
ME02548B (me) 2009-04-14 2017-02-20 Hra Pharma Lab Postupak za kontracepciju po potrebi
CN102107007B (zh) * 2011-01-28 2012-11-07 广州朗圣药业有限公司 甾体类抗孕激素组合物及其制备方法
CN102600001A (zh) * 2011-01-19 2012-07-25 国家人口计生委科学技术研究所 缓释米非司酮阴道环制剂及其应用

Also Published As

Publication number Publication date
MX362151B (es) 2018-12-24
EP2928499A1 (fr) 2015-10-14
UA115796C2 (uk) 2017-12-26
FR2999081B1 (fr) 2015-02-27
NI201500076A (es) 2015-11-13
EA201500609A1 (ru) 2015-09-30
CL2015001559A1 (es) 2016-01-04
BR112015013110A2 (pt) 2017-07-11
EA029701B1 (ru) 2018-05-31
WO2014087106A1 (fr) 2014-06-12
MD4591C1 (ro) 2019-04-30
MD20150060A2 (ro) 2015-10-31
CN105120899B (zh) 2018-07-24
DOP2015000137A (es) 2015-08-31
BR112015013110B1 (pt) 2020-07-14
ES2666618T3 (es) 2018-05-07
CR20150299A (es) 2015-08-14
FR2999081A1 (fr) 2014-06-13
MD4591B1 (ro) 2018-09-30
MX2015007127A (es) 2016-04-11
JP2016506390A (ja) 2016-03-03
EP2928499B1 (fr) 2018-01-31
CN105120899A (zh) 2015-12-02
ECSP15022501A (es) 2016-01-29
US20160213684A1 (en) 2016-07-28
GEP201706740B (en) 2017-09-25

Similar Documents

Publication Publication Date Title
PE20151783A1 (es) Dispersion solida de un modulador selectivo de los receptores de progesterona
CL2016001809A1 (es) Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x (divisional sol. n° 3344-15).
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
PE20151416A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
DK1768625T3 (da) Sammensætninger med vedvarende frigørelse indeholdende progesteron-receptormodulatorer
BR112015018094A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
CL2011000570A1 (es) Compuestos derivados de 3-(4-ciano-fenil)-pirazol-5-carboxamida, moduladores del receptor de progesterona; composicion farmaceutica; y su uso para el tratamiento de endometriosis, fibromiomas uterinos, dismenorrea primaria o secundaria, entre otras.
CL2015001652A1 (es) Compuestos derivados de 4-(bifenil-3-il)-7h-imidazo[4,5-c]piridazina, moduladores de la actividad del receptor gabaa; composicion farmaceutica que los comprende; combinacion que los comprende junto a un segundo agente farmaceuticamente activo; metodo de tratamiento del dolor; y su uso para el tratamiento del dolor.
PE20190502A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
PE20181925A1 (es) Composiciones antineoplasicas
CL2015000891A1 (es) Compuestos derivados de fenil-etinilo, moduladores de la actividad del receptor mglur5; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la ansiedad, dolor, depresion,entre otras.
JOP20190183A1 (ar) معدِلات مستقبلات الاستروجين
PE20141818A1 (es) Sistema para la administracion de farmacos
ECSP15022505A (es) Producto de comicronización que comprende un modulador selectivo del receptor de progesterona
HK1213487A1 (zh) 銅子宮環
EA201491614A1 (ru) Способ лечения гинекологических заболеваний
UY32005A (es) Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico a
BR112014018426A8 (pt) Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina
CL2015000053A1 (es) Composicion líquida oral pediátrica que comprende nepadutant y tpgs; proceso para prepararla; util en el tratamiento de enfermedades intestinales.
CU20100008A7 (es) Estratrienos 8-beta sustituidos como estrógenos de acción selectiva
CO2018000431A2 (es) Compuesto de imidazodiazepina
CU20140007A7 (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido- pirimidina y su uso como moduladores de receptores de c5a

Legal Events

Date Code Title Description
FG Grant, registration